Thursday 10/31 Insider Buying Report: PHAT, PGNY

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy — they expect to make money. So let's look at two noteworthy recent insider buys.

At Phathom Pharmaceuticals (PHAT), a filing with the SEC revealed that on Tuesday, Director Jonathan S. Edwards purchased 1,052,631 shares of PHAT, for a cost of $19.00 each, for a total investment of $20M. Edwards was up about 25.3% on the purchase at the high point of today's trading session, with PHAT trading as high as $23.80 in trading on Thursday. Phathom Pharmaceuticals is trading up about 0.9% on the day Thursday. This purchase marks the first one filed by Edwards in the past twelve months.

And also on Tuesday, Director Beth C. Seidenberg purchased $999,999 worth of Progyny (PGNY), purchasing 76,923 shares at a cost of $13.00 a piece. This buy marks the first one filed by Seidenberg in the past twelve months. Progyny is trading down about 0.6% on the day Thursday. So far Seidenberg is in the green, up about 26.9% on their purchase based on today's trading high of $16.50.

VIDEO: Thursday 10/31 Insider Buying Report: PHAT, PGNY

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos

BNK Invest

BNK Invest Inc. provides investment services and information. BNK Invest owns and operates a market news family of websites including DividendChannel, ETFChannel, StockOptionsChannel, and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual investors internationally.

Learn More